Graph for Max Amplitude/Length at G_y = 0. by Muhammad Hammad Bucha (21736111)

Subjects:

Graph for maximum Frequency at G_y = 0. by Muhammad Hammad Bucha (21736111)

Subjects:

Graph for maximum Power at G_y = 0. by Muhammad Hammad Bucha (21736111)

Subjects:

Summary of experimentation results. by Muhammad Hammad Bucha (21736111)

Subjects:

Piezoelectric eel. by Muhammad Hammad Bucha (21736111)

Subjects:

The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages. by Manuela Mally (348810)

Compatible pollen triggers a decrease in S-RNase transcript levels by a post-transcriptional mechanism. by Bolin Liu (59887)

Localization of key HH signaling proteins is impaired in <i>Ttbk2</i>^{<i>sca11/gt</i>} cilia. by Emily Bowie (543704)

The Transition from a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk by Heba M Ismail (9568748)

“…Conclusions</p> <p>A transition from an increase to a decrease in AUC C-peptide approximately 1.5 years pre-diagnosis was validated in two independent cohorts. …”

Correlates of osteogenic differentiation. by Fabian Westhauser (5314436)

A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner. by Shiva Mansouri (2838086)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

“…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …”

Table_1_Cysteinyl Leukotriene Receptor Antagonists Associated With a Decreased Incidence of Cancer: A Retrospective Cohort Study.docx by Ha Young Jang (1522204)

“…The cancer risk showed a tendency to decrease rapidly when LTRAs were used in high dose (aHR = 0.56, 95% CI = 0.40–0.79) or for longer durations of more than 3 years (aHR = 0.68, 95% CI = 0.60–0.76) and 5 years (aHR = 0.33, 95% CI = 0.26–0.42). …”

BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i>^<i>ECKO</i> mice and lesions in the retina of <i>Ccm2</i>^<i>ECKO</i> mice. by Jia Li (160557)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects: